Clinical trials: Exudative Age-Related Macular Degeneration
Nonexudative Age-related Macular Degeneration
Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration
Study to evaluate the safety and tolerability of MC-1101, a potential topical treatment for non-edxudative age Related Macular Degeneration (AMD) in medically stable individuals.
- Trial name
- NCT01922128
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- MacuCLEAR, Inc.
Macular Degeneration
Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)
This is s randomized, multi-center, double blind, 3 arm, phase I/II pilot study to evaluate the safety and efficacy of treatment with ORA102 combined with Avastin (Bevacizumab) versus Avastin alone, in patients with neo-vascular…
- Trial name
- NCT00745511
- Testing
- ORA102 and Avastin, Avastin
- Where
- 5 sites in Israel
- Volunteers
- 96 people
- Sponsor
- Ora Bio Ltd.
Age Related Macular Degeneration
Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)
The purpose of this first in man study is to examine the safety of an experimental gene transfer agent, RetinoStat, designed to treat neovascular age-related macular degeneration.
- Trial name
- GEM (NCT01301443)
- Testing
- Subretinally injected RetinoStat
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Oxford BioMedica
Age Related Macular Degeneration
Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy
The rationale for evaluating LucentisTM (a recombinant humanized anti-human Vascular Endothelial Growth Factor (VEGF) monoclonal antibody (Fab) in patients with neovascular (wet) Age related Macular Degeneration (AMD) is based on…
- Trial name
- FVF4193s (NCT01255774)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The New York Eye & Ear Infirmary
Macular Degeneration
An Extension to Study MD7108240
This is a two month study to allow continued treatment with pazopanib eye drops. Study may be extended to 5 months.
- Trial name
- NCT00733304
- Testing
- Pazopanib
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 42 people
- Sponsor
- GlaxoSmithKline
Neovascular Age-related Macular Degeneration
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A multicentre, randomised, parallel group, sham-controlled, double-masked, dose-ranging study, investigating two doses of OPT-302 in combination with ranibizumab compared with ranibizumab with sham, over six consecutive monthly…
- Trial name
- NCT03345082
- Testing
- OPT-302, ranibizumab
- Where
- 108 sites in United States, Czechia and 8 more
- Volunteers
- 366 people
- Sponsor
- Opthea Limited
Diabetic Retinopathy, Retinal Vein Occlusion
Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
Blindness can be caused by many ocular diseases, such as diabetic retinopathy, retinal vein occlusion, age-related macular degeneration, pathologic myopia and glaucoma.
- Conditions
- Diabetic Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion, Central Serous Chorioretinopathy
- Trial name
- NCT04723160
- Testing
- Software assisted imaging diagnosis
- Where
- 5 sites in China
- Volunteers
- 748 people, healthy volunteers welcome
- Sponsor
- Visionary Intelligence Ltd.
Age-Related Macular Degeneration, Macular Degeneration
Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration
To evaluate the visual outcome and number of injections required during an optical coherence tomography (OCT)-guided treat and extend regimen with intravitreal aflibercept for treatment of subfoveal neovascular age-related…
- Trial name
- ATLAS (NCT01773954)
- Testing
- Intravitreal Aflibercept Injection
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- MidAtlantic Retina
Macular Degeneration
Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.
In this clinical study researchers want to gain a deeper understanding of treatment consistence under real world conditions over the course of 24 months of Aflibercept injections into the eye for patients suffering from abnormal…
- Trial name
- ANDROMEDA (NCT03714308)
- Testing
- Ivt. Aflibercept (Eylea, BAY86-5321)
- Where
- Germany
- Volunteers
- 554 people
- Sponsor
- Bayer
Neovascular Age-Related Macular Degeneration
Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
The PrONTO Study was designed to evaluate the response of neovascular age-related macular degeneration (AMD) patients to intravitreal Lucentis using Optical Coherence Tomography (OCT) imaging.
- Trial name
- NCT00344227
- Testing
- Lucentis (Ranibizumab)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Miami
Neovascular Age-related Macular Degeneration (AMD)
Progression Suppression and Retinal Regression in VEGF-resistant AMD
The goal of this clinical trial is to assess safety and efficacy in patients with Neovascular Age-related Macular Degeneration with no response to existing therapy.
- Trial name
- PRESERVE (NCT07005323)
- Testing
- Pars plana vitrectomy
- Where
- 3 sites in Japan
- Volunteers
- 10 people
- Sponsor
- PharmaBio Corporation
Exudative Age-related Macular Degeneration
Intravitreal Aflibercept for Submacular Hemorrhage
The prognosis of exudative age-related macular degeneration (AMD) accompanied by submacular hemorrhage is generally poor. A recently developed anti-VEGF agent eyeliaTM is also a useful treatment option for exudative AMD.
- Trial name
- NCT03169660
- Testing
- Vascular endothelial growth factor trap-eye
- Where
- South Korea
- Volunteers
- 29 people
- Sponsor
- Kim's Eye Hospital
Neovascular Age Related Macular Degeneration
Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
This was a multicenter, open label study that is designed to evaluate the safety of brolucizumab 6 mg in a prefilled syringe in subjects with neovascular age related macular degeneration and to support collection of observations…
- Trial name
- NCT03930641
- Testing
- RTH258
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-Related Macular Degeneration
A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
RAZORBILL was an observational, multicenter, multinational, open-label, study designed primarily to investigate the influence of automated OCT image enrichment with segmentation information on disease activity assessment in nAMD…
- Trial name
- RAZORBILL (NCT04662944)
- Testing
- brolucizumab, ranibizumab, aflibercept
- Where
- 17 sites in Canada, Germany and 3 more
- Volunteers
- 494 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
- Conditions
- Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration
- Trial name
- NCT06190093
- Testing
- bevacizumab, ranibizumab
- Where
- 61 sites in United States
- Volunteers
- 400 people
- Sponsor
- Outlook Therapeutics, Inc.
Wet Macular Degeneration
Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse
Age-related macular degeneration (AMD) is a chronic and progressive eye disease and is one of the leading causes of vision impairment globally.
- Trial name
- NCT05211804
- Testing
- Ophthalmic Drugs
- Where
- Norway
- Volunteers
- 31 people
- Sponsor
- Sorlandet Hospital HF
Neovascular Age-related Macular Degeneration
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)
The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept intravitreal (IVT) injection as compared to the approved vascular endothelial growth factor (VEGF) antagonist active…
- Trial name
- NCT03630952
- Testing
- 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection
- Where
- 154 sites in United States, Bulgaria and 10 more
- Volunteers
- 1,157 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Age-Related Macular Degeneration
Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
This open-label study is being conducted to evaluate the initial safety and tolerability of BBC1501 IVT in patients with nAMD. The primary objective of this study is to evaluate the safety and tolerability of 3 ascending doses of…
- Trial name
- NCT05803785
- Testing
- BBC1501
- Where
- 2 sites in Australia
- Volunteers
- 18 people
- Sponsor
- Benobio Co., Ltd.
Neovascular Age-Related Macular Degeneration
A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration
This is a multicenter, open-label study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of multiple intravitreal injection TK001 in patients with AMD.
- Trial name
- NCT03021785
- Testing
- TK001
- Where
- 5 sites in China
- Volunteers
- 36 people
- Sponsor
- Jiangsu T-Mab Biopharma Co.,Ltd
Geographic Atrophy
Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)
This is a prospective, randomized study to evaluate the efficacy and safety of ORACEA® in the treatment of geographic atrophy due to dry age-related macular degeneration (AMD).
- Trial name
- TOGA (NCT01782989)
- Testing
- ORACEA®
- Where
- 37 sites in United States
- Volunteers
- 286 people
- Sponsor
- Paul Yates, MD, PhD